1. Introduction
Weight loss, overweight or obese PCOS-affected, PCOS, overweight, weight loss
OBESE, POLYCYSTIC OVARY SYNDROME (PCOS), MAY, METABOLIC DISORDERS, POLYCYSTIC OVARY SYNDROME, INSULIN SENSITIVITY
These authors contributed equally to this work.The effects of dulaglutide and a calorie-restricted diet (CRD) on visceral adipose tissue (VAT) and metabolic profiles in polycystic ovary syndrome (PCOS) have not been extensively investigated. In this study, we investigated whether dulaglutide combined with CRD could further reduce VAT and promote clinical benefits as compared with a CRD regimen alone in overweight or obese PCOS-affected women. Between May 2021 and May 2022, this single-center, randomized, controlled, open-label clinical trial was conducted. Overall, 243 participants with PCOS were screened, of which 68 overweight or obese individuals were randomly randomized to undergo dulaglutide combined with CRD treatment (Polycystic ovary syndrome (PCOS) is a unification of reproductive endocrine and metabolic disorders that affects 6–20% of reproductive-aged women [Lifestyle and weight management, particularly dietary intake aimed at weight loss, are initial treatment strategies for PCOS. Weight loss of 5–10% from baseline body weight ameliorates insulin sensitivity and the ovulation rate, and decreases hyperandrogenism among the overweight/obese PCOS population [Glucagon-like peptide 1 (GLP-1) is a peptide hormone released by gut enteroendocrine cells that improves glucose homeostasis and reduces body weight [